Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Thursday, Goldman Sachs revised its price target for Arvinas Inc. (NASDAQ:ARVN) shares, reducing it to $8 from the previous $12, while keeping a Neutral rating on the stock. The company’s shares currently trade at $7.23, with InvestingPro analysis indicating the stock is currently undervalued based on its Fair Value assessment. The adjustment follows news that Arvinas and its partner Pfizer (NYSE:PFE) have decided to halt their plans for Phase 3 trials in first-line (1L) and second-line (2L) treatments for ER+ breast cancer. This strategic shift is part of Arvinas’s broader cost reduction efforts aimed at extending its cash runway into the second half of 2028, which will provide time for the company’s earlier-stage pipeline to mature.
Stifel analysts noted that Arvinas shares have significantly underperformed compared to the broader market, with a roughly 25% drop versus a marginal 0.5% intraday decline in the XBI biotech index. InvestingPro data reveals the stock’s high volatility with a beta of 2.32 and a dramatic 70% decline over the past year. The company’s market capitalization now stands at approximately $499 million. This underperformance is largely attributed to the market’s reaction to the discontinuation of the two planned Phase 3 trials. The halted trials were anticipated to be pivotal for the combination therapies with atirmociclib in the 1L setting and a CDK4/6 inhibitor in the 2L setting for ER+/HER2- breast cancer.
The discontinuation effectively narrows the potential market for Arvinas’s drug candidate vepdegestrant, confining its use to patients with 2L+ ESR1 mutation-positive breast cancer. This limitation has prompted the reassessment of Arvinas’s stock value by Goldman Sachs.
Despite the setback, Arvinas is pressing forward with its strategy to reduce costs and focus on its early-stage drug pipeline. The company aims to stretch its financial resources to allow these developmental drugs more time to progress and potentially reach the market. According to InvestingPro data, Arvinas maintains a healthy current ratio of 4.64 and holds more cash than debt, though it’s currently burning through cash at a significant rate.
Goldman Sachs’s updated price target of $8 reflects the new trajectory for Arvinas, taking into account the reduced market opportunities following the halted trials and the company’s strategic realignment. The firm maintains its Neutral stance, indicating a wait-and-see approach as Arvinas navigates this period of transition and development. For deeper insights into Arvinas’s financial health and growth prospects, investors can access comprehensive analysis and 13 additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Arvinas Inc. reported impressive financial results for the first quarter of 2025, with revenue reaching $188.8 million, far exceeding analyst forecasts of $42.16 million. The company’s earnings per share (EPS) also impressed at $1.14. Despite these strong financial outcomes, Arvinas has faced challenges, including a strategic decision to reduce its workforce by approximately one-third, which may have affected investor sentiment. The company has also aligned with Pfizer to remove two Phase III trials from their joint development plan. Arvinas plans to focus on filing regulatory applications for its drug Vepdeg in the coming months. Additionally, the company has extended its cash runway into the second half of 2028, supported by cost reduction initiatives. Analyst discussions highlighted the company’s potential in the ESR1 mutant breast cancer market, with ongoing collaborations with Pfizer. Arvinas continues to advance its pipeline, with positive trial results for its Vepdeg and other promising developments in its neuroscience and oncology programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.